Study of the impact of viral load of hepatitis C on patients with concomitant psoriasis vulgaris

Taha, Emad A.; Mekky, Mohamed A.; Morsy, Hanan; Saleh, Medhat A.; Nafeh, Hanan M.; Ez-Aldin, Azza M.; Sayed, Sohair K.

doi:10.1016/j.ajg.2014.08.001

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas an epidemiological association between psoriasis vulgaris and hepatitis C virus infection has been reported in the past (4,5), data about the pathogenetic interaction of both conditions are very limited. It is suggested that hepatitis C virus infection itself especially may trigger late-onset psoriasis vulgaris via tumour necrosis factor (TNF)-α, which acts as a common mediator in both diseases (4).…”

Section: Discussionmentioning

confidence: 99%

Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir

Heppt¹,

Sticherling²

2017

Acta Derm Venerol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir

Heppt¹,

Sticherling²

2017

Acta Derm Venerol

View full text Add to dashboard Cite

“…The increased cutaneous levels of cathelicidin, TLR9 and IFNc of HCV-positive psoriatic patients as compared to HCV-negative psoriatics suggest that HCV infection may predispose patients to developing psoriasis[ 7 ]. These findings seem to be confirmed clinically due to the worse prognosis of psoriasis in HCV-positive patients[ 7 , 25 ]. The mean PASI score is significantly higher in cohorts of patients affected with hepatitis C than those with psoriasis alone[ 7 , 25 ].…”

Section: Discussionmentioning

confidence: 79%

“…These findings seem to be confirmed clinically due to the worse prognosis of psoriasis in HCV-positive patients[ 7 , 25 ]. The mean PASI score is significantly higher in cohorts of patients affected with hepatitis C than those with psoriasis alone[ 7 , 25 ].…”

Section: Discussionmentioning

confidence: 79%

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

Damiani

Franchi

Pigatto

et al. 2018

WJH

View full text Add to dashboard Cite

AIMTo evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) compared to pegylated interferon-2α plus ribavirin (P/R) therapy.METHODSThis is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus (HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017. The patients were divided into two groups: patients that underwent therapy with DAAs and patients that underwent HCV treatment with P/R. Patients were assessed by a dermatologist for psoriasis symptoms, collecting Psoriasis Area Severity Index (PASI) scores and the Dermatology Quality of Life Index (DLQI). PASI and DLQI scores were evaluated 24 wk after the end of HCV treatment and were assumed as an outcome of the progression of psoriasis. Switching to a different bDMARD was considered as an inadequate response to biological therapy. The dropout of HCV therapy and sustained virological response (SVR) were considered as outcomes of HCV therapy.RESULTSFifty-nine psoriatic patients in biological therapy underwent antiviral therapy for CHC. Of this, 27 patients were treated with DAAs and 32 with P/R. After 24 wk post treatment, the DLQI and the PASI scores were significantly lower (P < 0.001 and P < 0.005, respectively) in the DAAs group compared with P/R group. None of the patients in the DAAs group (0/27) compared to 8 patients of the P/R group (8/32) needed a shift in biological treatment.CONCLUSIONDAAs seem to be more effective and safe than P/R in HCV-positive psoriatic patients on biological treatment. Fewer dermatological adverse events may be due to interferon-free therapy.

show abstract

“…This finding reflects the results of a study conducted in Egypt, in which the average PASI score of HCV-positive psoriatic patients was higher than HCV-negative psoriasis patients. 54 We therefore postulate that if inflammatory genes, such as TLR9 and cathelicidin, are upregulated in HCV infection, then not only does this predispose patients to psoriasis, but may even increase the severity of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C may enhance key amplifiers of psoriasis

Chun

Afshar

Audish

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Study of the impact of viral load of hepatitis C on patients with concomitant psoriasis vulgaris

Cited by 6 publications

References 28 publications

Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir

Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

Hepatitis C may enhance key amplifiers of psoriasis

Contact Info

Product

Resources

About